Return to homepagePandemic Pact

Regulation of macrophage extravasation by α2 adrenergic agonists in CTS associated with COVID-19

  • Funded by National Institute of Health Carlos III [El Instituto de Salud Carlos III] (ISCIII)
  • Total publications:0 publications

Grant number: COV20_00932

Grant search

Key facts

  • Disease

    COVID-19

  • Start & end year

    N/A

  • Funder

    National Institute of Health Carlos III [El Instituto de Salud Carlos III] (ISCIII)

  • Principal Investigator

    José Federico Díaz González

  • Research Location

    Spain

  • Lead Research Institution

    Fundación Canaria Instituto de Investigación Sanitaria de Canarias (FIISC)

  • Research Priority Alignment

    N/A

  • Research Category

    Pathogen: natural history, transmission and diagnostics

  • Research Subcategory

    Immunity

  • Special Interest Tags

    N/A

  • Study Type

    Non-Clinical

  • Clinical Trial Details

    N/A

  • Broad Policy Alignment

    Pending

  • Age Group

    Unspecified

  • Vulnerable Population

    Unspecified

  • Occupations of Interest

    Unspecified

Abstract

Patients with severe COVID-19 develop cytokine storm syndrome (CTS) that seriously worsens their prognosis. CTS is characterized by an excessive accumulation of activated macrophages that cause a massive release of pro-inflammatory cytokines. Macrophage depletion in the development of STC has been reported to decrease lethality in several animal models. Data from our laboratory demonstrate that α2 adrenergic receptor agonists prevent the accumulation of neutrophils in the inflammatory focus and preliminary results have shown a similar anti-inflammatory effect in circulating monocytes. The main objective of this project is to generate the mechanistic rationality that allows supporting α2 adrenergic agonists as modulators of the migration of monicycles to the inflammatory focus, in order to prevent / treat COVID-19 patients who develop CTS.